Medican Enterprises Inc (MDCN)

[vegasvic]

A MUST READ 4 NEW TRADERS, DUE DILLEGENCE Huge MDCN, IHMML/Zenabis, & Other Deals in Play...

This huge MDCN deal with IHMML/Zenabis is still in play to be closed per the recent 10-Q that was filed with the SEC by MDCN:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114386745

I will reflect how this deal alone is worth well over $160 Million and what such would potentially mean for MDCN from this deal alone, but first read the info below to fully understand its origination.

Medican is in negotiations to obtain 51% of IHMML/Zenabis:
http://www.medicaninc.com/2014/06/30/medican-is-in-negotiations-to-obtain-51-of-ihmml/

http://www.zenabis.com/


Medican Enterprises, Inc. (OTCBB: MDCN) a bio-pharmaceutical company in the emerging global medical marijuana industry is pleased to announce it is currently negotiating the purchase of 51% of International Herbs Medical Marijuana Ltd (“IHMML”). ...

http://www.digitaljournal.com/pr/1785090
International Herbs Medical Marijuana Ltd. (IHMML), branded under the name Zenabis, is pleased to announce that it will locate its world-class medical marijuana facility in Atholville, New Brunswick. The site selection comes after an exhaustive months-long process. ...

In the 400,000 square foot former Atlantic Yarns building, IHMML will build a world-class facility that will produce pharmaceutical-grade medical marijuana under Health Canada's new Marihuana for Medical Purposes Regulations (MMPR). IHMML will conduct research and development, cultivate, dry, package and dispense medical marihuana for registered Canadian patients, as well as provide patient support services to its customers. ...

The building will be retrofitted to meet the highest level of protection required for the site, for approval by Health Canada. Health Canada's new program allows companies such as IHMML to provide Canadians with medical marijuana, produced with the highest standards in the most secure setting.

IHMML's business plan will make it one of the largest medical marijuana facilities in North America, creating over 1,000 new, full time jobs throughout four phases, in northern New Brunswick.

"After working closely with officials at all three levels of government, along with educational, industry and community partners, we are fully confident that together, Restigouche County will become a continental leader in this important emerging market ", added Coft. IHMML took possession of the building on March 10th, 2014.

About International Herbs Medical Marijuana Ltd. (IHMML): IHMML is committed to providing Canadian patients with access to a regulated and trusted supply of pharmaceutical-grade cannabis and cannabis products in accordance with the national Marihuana for Medical Purposes Regulations (MMPR). We aim to aid in the relief of the chronic disabilities and terminal illnesses with which are patients are challenged, while holding ourselves to a higher level of safety and reliability in both our products and pharmaceutical standards. www.zenabis.com.

ttp://www.zenabis.com/#our-vision


http://www.zenabis.com/#our-team


http://www.zenabis.com/#our-facility




http://botecanalysis.com/

http://botecanalysis.com/we-are/


http://liq.wa.gov/publications/Marijuana/BOTEC%20reports/5a_Cannabis_Yields-Final.pdf
Estimating Adequate Licensed Square Footage for Production
Jonathan Caulkins, BOTEC Analysis, Carnegie Mellon University
Matthew Cohen, TriQ Inc.
Luigi Zamarra

Within the BOTEC links and the IHMML/Zenabis data above, the below data has been confirmed as ”Key Variables” to consider:

** The BOTEC data is drawn from a review of the relevant literature and from research and interviews conducted with 16 growers.
** This BOTEC report finds that indoor and outdoor yields average about 40 grams per square foot per harvest, but with a considerable range.
** Yields per square foot per year can be much higher of course, because there can be multiple harvests per year, particularly for indoor production.
** Indoor production allows 4-6 harvests per year (5 being typical), whereas outdoor production allows only 1-3 harvests per year.
** Thus, production per square foot per year is much higher with indoor growing.
** IHMML/Zenabis has a 400,000 square foot world-class facility that will produce pharmaceutical-grade medical marijuana under Health Canada's new MMPR.
** Will be one of the largest medical marijuana facilities in North America.
** Will create over 1,000 new full time jobs.
Marijuana Industry experts estimate that the average price of a gram of medical cannabis is $12 to $15 per gram. This can be learned by simply researching such information.

BOTEC speculated production cost of marijuana ranges from $2 to $3 per gram:
http://liq.wa.gov/publications/Marijuana/BOTEC%20reports/8a_Impact_of_tax_scheme_on_price_of_regulated_cannabis-Final.pdf

** After doing further research, the norm throughout is approximately $1 to $2 per gram as the cost to produce good marijuana indoors.

** We will be conservative and consider a median cost of $2 per gram instead of $1 or $3 per gram to cover any Net Expenses.

** That’s roughly around $10.00 per gram for a Net Profit.

Now let’s derive a valuation considering the 400,000 Square Feet Facility:

400,000 Square Feet x 40 Grams Per Square Foot = 16,000,000 Grams
16,000,000 Grams x $10.00 Per Gram (Net Profit) = $160,000,000 Net Profit In MJ Production

$160,000,000 Net Profit in MJ Production x 4 Harvest Per Year = $640,000,000 “Potential” Net Income Per Year

The Outstanding Shares (OS) is the key fundamental denominator that is used to assess the fundamental valuation of a company to help derive the Earnings Per Share (EPS) for a company. Since the Authorized Shares (AS) was last confirmed to be 1 Billion shares, courtesy of ”beer$$money”, I will consider a valuation as if the AS has been maxed out to 1 Billion shares as a worst case scenario:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114452409

Now let’s derive a potential EPS from the info that we have available to consider. To do this, we must divide the Net Profit/Income by the OS to get the EPS as derived from the formula below:

Net Income ÷ Outstanding Shares (OS) = Earnings Per Share (EPS)

So…

$640,000,000 Net Income ÷ 1,000,000,000 Shares (OS) = .64 EPS

To determine where a stock should fundamentally trade, multiply the EPS with the Price to Earnings (P/E) Ratio. For inquiring minds, the P/E Ratio is basically the ”Growth Rate” for a group of similar stocks within a particular Sector or Industry for where a stock would be classified to exist/trade. As that stock exists within that particular Sector or Industry, it is expected to grow at the same rate as such like stocks within that Sector or Industry. For those new for understanding what a P/E Ratio is, read the links below that hopefully will help:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=57154170
http://www.investopedia.com/terms/p/price-earningsratio.asp

From the links above, it was indicated that 20 – 25 is considered the Average P/E Ratio to consider within the market for stocks that experience a fair amount of growth. For the purpose of this post, I will use 20 for the average/conservative P/E Ratio. Consider below…

EPS x P/E Ratio = Fundamental Share Price

So…

.64 EPS x 20 P/E Ratio = $12.80 per share

This means that given all of the considered variables above, the Fundamental Share Price for which MDCN should trade should be within the $12.80 per share price range if all of the stars align according to the above. If you do the math with the 778 Million OS, then the $16.44 per share price range would be warranted. Please understand, this post is not the gospel. This post is basically nothing more than ”speculation” that is derived from what MDCN had indicated within their recent 10-Q filed with the SEC below:
http://ih.advfn.com/p.php?pid=nmona&article=66951894

As for most or almost all stocks within the penny stock world, the stars usually don’t align for whatever has been positively speculated about a stock with such a huge magnitude. Please know that me posting these thoughts will not be the justification for any kind of significant price movement and price sustainment. Such will be justified by the ”substance” that MDCN publicly releases to confirm its growth.

Please use the Substitution Property to substitute out any variable that might change later in the future such as the amount of Net Income or particularly the amount for the OS if it increases. Still, consider now if I am only half right… or a third right… or a quarter right… or even a tenth right… with my thoughts above.



More food for thought is to consider that MDCN is expected to be providing more updates regarding it’s California venture that was PR-ed below:

Quote:
--------------------------------------------------------------------------------

http://finance.yahoo.com/news/medican-expands-scope-leasing-dispensary-120000873.html
Medican Expands Scope of Leasing and Dispensary Opportunities to California; Announces Execution and Closing of Lease Agreement with Breeding Rare Cannabis Original Genetics Inc.

Medican US, the U.S. subsidiary of Medican Enterprises Inc. (MDCN) (“Medican” or “the Company”), a merchant bank and bio-pharmaceutical company in the emerging global marijuana industry, today announced that the Company has executed and closed a lease agreement expanding its real estate and leasing business into California with Breeding Rare Cannabis Original Genetics Inc. (“BRCOG”).

This new agreement specifies that BRCOG will lease the indoor warehouse, outdoor greenhouse and R&D property for $9000 USD per month for a minimum initial lease term of five years, and the first right of refusal for an additional five-year term. Under the terms of the agreement, Medican will provide lease improvements by way of financing, equipment and grow technologies.

“We are pleased to have secured a lease agreement with an experienced industry leader such as Medican,” said Mr. R. White, CEO of BRCOG. “I am excited about the synergies this new relationship with Medican brings and look forward to maximizing the productivity of our production and R&D businesses.”

The property is located in Anza, California and is the first of several planned projects. According to market research by the ArcView Group the cannabis marketplace grew 74% in 2014 to $2.7 billion in the U.S., with California comprising 49 percent of the market.

“We are thrilled to be working with BRCOG in the California market,” stated Ken Williams, CEO of Medican Enterprises. “Finding and developing leasing locations such as this, provide Medican with geographically desirable and lucrative business opportunities. We have several more projects planned in California in the coming weeks and look forward to expanding our relationship with BRCOG as we continue to drive value for shareholders.”

About Medican Enterprises, Inc.

Medican Enterprises is a bio-pharmaceutical company focused on pursuing business opportunities in the growing medical and recreational marijuana sector. Through its subsidiaries, Medican is seeking to invest in our businesses associated with the growing, marketing, research and development, training, distribution and retail sale of medical and recreational marijuana, both in the United States and Canada. For more information visit: www.medicaninc.com.

--------------------------------------------------------------------------------




I think some key ”networking” has transpired that is very positive in regards to the deal that MDCN closed below with having Hemp Health Inc. of Carlsbad, California as their first client:

https://hemphealthinc.com/


Quote:
--------------------------------------------------------------------------------

http://finance.yahoo.com/news/medican-enterprises-files-8k-announcing-120000509.html
Medican Enterprises Inc. (MDCN) (“Medican” or “the Company”), a merchant bank and bio-pharmaceutical company in the emerging global marijuana industry, announces that further to its press release of April 28, 2014 the Company has closed on its acquisition of TWYNS, a company that provides branding services for enterprises in the Cannabidiol (CBD) business. The transaction is valued at approximately $1,000,000, all in stock and is expected to add approximately $400,000 to Medican’s annual revenues.

“TWYNS business plan extends the sale of CBD to more consumers globally through strategic branding,” stated Ken Williams, CEO of Medican Enterprises. “The model is Coca-Cola’s very successful bottling distributing arrangement. We believe that cannabis will be a cottage industry for the foreseeable future, with each regulated jurisdication demanding fees and licenses. TWYNS will provide local growers, product manufacturers and distributors with a reliable ‘seal of approval’ that ensures quality and provides the consumer with a reliable benchmark.”

“TWYNS also helps drive long term value for shareholders,” continued Williams. “It will generate immediate profits from both licensing and certification businesses without capital costs or operational overhead. In addition, the Company is also partnered to sell quality tinctures and edibles. Sales of its signature infused products are expected to expand dramatically as well as sale of very high quality CBD oil to other companies.”

Unlike medical marijuana, which is produced primarily from strains of cannabis designed to deliver high levels of THC, CBD products can be extracted from industrial hemp, the high CBD, low THC strain used to produce textiles, ropes, resins, paper and other industrial materials.

TWYNS offers licensing on commercial art work and its unique E-MC2 trademark to manufactures of supplements, salves, lotions, and edibles. In exchange, it will receive royalties from CBD wellness product sales around the world. The company’s first client Hemp Health Inc. of Carlsbad, California, is a pioneer in hemp cannabidiol (CBD) products, imports and manufactures a variety of CBD products such as oil, spray and capsule form.

TWYNS will also provide trademarked packaging to CBD and THC dispensaries offering placement windows for both constituents -- the empty window in the copyrighted box can be filled with their own or the customer’s choice of THC. TWYNS will receive a fee to license out the marketing space, or resell an empty bottle to fill the window with a THC of the customer’s choice.

In addition to the licensing business to wholesalers, TWYNS will provide cannabis growers with a free license to gain recognition beyond the local promotion they would otherwise be limited to.

“Expansion to any town city or state requires permitting, licensing, specific build outs etc, so that simply to go from one town in, say Colorado, to another could require an upfront investment into the hundreds of thousands,” said Jay Gordon, CEO of TWYNS. “It is that situation that makes the market ripe for a branding program such as ours to overlay the cottage industry and generate income as well as providing superior products.”

About Medican Enterprises, Inc.

Medican Enterprises is a bio-pharmaceutical company focused on pursuing business opportunities in the growing medical and recreational marijuana sector. Through its subsidiaries, Medican is seeking to invest in our businesses associated with the growing, marketing, research and development, training, distribution and retail sale of medical and recreational marijuana, both in the United States and Canada. For more information visit: www.medicaninc.com.

--------------------------------------------------------------------------------




I think it is fair to expect to see an update on this previous news below which could warrant a share price valuation roughly around a third of the valuation indicated earlier within this post:

Quote:
--------------------------------------------------------------------------------

http://finance.yahoo.com/news/medican-enterprises-extends-closing-two-120000157.html
Medican Enterprises Extends Closing on Two Phoenix Area Properties

Medican Enterprises Inc. (MDCN) (“Medican” or “the Company”), a merchant bank and bio-pharmaceutical company in the emerging global marijuana industry, is pleased to announce that it continues to raise capital in the market place and has extended the option to purchase two facilities in the Phoenix, AZ, area.

The first facility located in Phoenix has a total retail footprint of 7,200 sq. ft. and is currently leased to a licensed medical marijuana dispensary. Subject dispensary currently pays $15,000 a month in rent, plus additional rent of 30% of gross sales. A real-estate appraisal conducted by Kalinowski & Associates dated December 24, 2014, values the property at $2,385,000. Note this is a conservative valuation as it only considers the guaranteed lease income of $15,000 a month and not the additional rent from gross sales. Business at this dispensary is progressing solidly, and Medican believes it has tremendous potential to increase sales due to the growth of the surrounding area.

The second site is also located in the Phoenix area and has a total building footprint of 66,000 sq ft. Medican plans to acquire the site and lease it to a licensed medical marijuana grower as a fully built facility. Commercial terms pertaining to the lease are still being finalized. An appraisal report by Kalinowski & Associates dated February 9, 2015, confirms an evaluation of $2,340,000 without any additional consideration as a medical marijuana facility.

“We appreciate the patience demonstrated by the sellers of the two sites. It is apparent that industry participants believe in our vision, and we are keen to close both transactions,” stated Ken Williams, CEO of Medican Enterprises.

Medican Enterprises continues to evaluate new business opportunities on a regular basis and marijuana business opportunities with Medican Nations Inc., our first nations division.

In December 2014, the US Department of Justice instructed all United States Attorneys not to prevent the growing or sale of marijuana on sovereign tribal land. Timothy Purdon, the U.S. attorney for North Dakota and the chairman of the Attorney General's Subcommittee on Native American Issues, stated, “The tribes have the sovereign right to set the code on their reservations.”

Medican is aware of the problems alcohol has brought to Native Americans and desires to work with tribes in developing cannabis in ways that protect the First Nations and respect their rights, including the right not to develop it.

About Medican Enterprises, Inc.

Medican Enterprises is a bio-pharmaceutical company focused on pursuing business opportunities in the growing medical and recreational marijuana sector. Through its subsidiaries, Medican is seeking to invest in our businesses associated with the growing, marketing, research and development, training, distribution and retail sale of medical and recreational marijuana, both in the United States and Canada. For more information visit: www.medicaninc.com.

--------------------------------------------------------------------------------


v/r
Sterling